uniQure (NASDAQ:QURE) Share Price Passes Below 50 Day Moving Average Following Insider Selling

uniQure N.V. (NASDAQ:QURE) shares crossed below its fifty day moving average during trading on Monday after an insider sold shares in the company. The stock has a fifty day moving average of $14.29 and traded as low as $13.65. uniQure shares last traded at $13.95, with a volume of 1,978,275 shares trading hands.

Specifically, insider Jeannette Potts sold 4,670 shares of the company’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $15.14, for a total transaction of $70,703.80. Following the completion of the sale, the insider now owns 115,073 shares of the company’s stock, valued at $1,742,205.22. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Wall Street Analysts Forecast Growth

QURE has been the subject of several recent analyst reports. Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Cantor Fitzgerald raised shares of uniQure to a “strong-buy” rating in a report on Monday, May 19th. Chardan Capital reissued a “buy” rating and issued a $38.00 target price on shares of uniQure in a report on Friday, May 30th. Finally, Guggenheim reissued a “buy” rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.82.

uniQure Price Performance

The firm has a market cap of $764.18 million, a price-to-earnings ratio of -3.18 and a beta of 0.08. The business’s 50-day simple moving average is $14.29 and its two-hundred day simple moving average is $13.99. The company has a current ratio of 11.99, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. As a group, research analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. bought a new stake in shares of uniQure in the 4th quarter valued at $320,000. Raymond James Financial Inc. bought a new stake in shares of uniQure in the 4th quarter valued at $1,951,000. Monaco Asset Management SAM bought a new stake in shares of uniQure in the 4th quarter valued at $2,414,000. Twin Tree Management LP bought a new stake in shares of uniQure in the 4th quarter valued at $77,000. Finally, JPMorgan Chase & Co. increased its stake in shares of uniQure by 14.7% in the 4th quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company’s stock valued at $8,014,000 after acquiring an additional 58,246 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.